Drugs

, Volume 33, Supplement 2, pp 97–102 | Cite as

Specific Effects of Cyclandelate on Memory

  • Jambur Ananth
Section 2: Clinical Studies

Summary

In an uncontrolled clinical trial of 6 weeks’ duration conducted in 20 male patients, aged 49 to 68 years, with memory disorders, cyclandelate 1200 to 1600mg daily was found to be effective in improving memory as reflected by psychiatric, psychometric and psychophysiological measurements. Treatment with cyclandelate produced clinical effects which were selective for the Wechsler Memory Scale items of visual reproduction and orientation — indicators of the declarative memory. Moreover, the improvements seen in the average auditory reaction and critical flicker fusion frequency demonstrates its effect on procedural memory. Thus, our results indicate that this drug may be therapeutically useful in memory disorders of various aetiology, and that further exploration of the place of cyclandelate in this clinical area is needed.

Keywords

Intermittent Claudication Declarative Memory Mandelic Acid Procedural Memory Memory Disorder 

Résumé

Lors d’une étude ouverte de 6 semaines conduite chez 20 patients de sexe masculin, âgés de 49 à 68 ans et atteints de troubles mnésiques, des doses de 1200 à 1600 mg/jour de cyclandélate ont amélioré la mémoire, comme en ont témoigné les mesures psychiatriques, psychométriques et psychophysiologiques. Le traitement par le cyclandélate a produit des effets cliniques sélectifs des items de reproduction visuelle et d’orientation de l’échelle mnésique de Wechsler, qui sont des indicateurs de la mémoire déclarative. De plus, les améliorations des réactions auditives moyennes et de la fréquence critique de fusion mettent en évidence les effets du cyclandélate sur la mémoire opérative. Nos résultats indiquent donc que ce médicament peut être utile au traitement de troubles mnésiques d’étiologie variée et qu’il est nécessaire d’étudier de façon plus approfondie la place du cyclandélate dans ce domaine clinique.

Riassunto

In una sperimentazione clinica, non controllata, della durata di 6 settimane, condotta su 20 pazienti maschi dai 49 ai 68 anni di età, con turbe délia memoria, si riscontrò che 1200–1600 mg al giorno di ciclandelato erano efficaci nel miglioramento délia memoria, dati confermati da determinazioni psichiatriche, psicometriche e psicologiche. Il trattamento con ciclandelato produceva degli effetti clinici che erano selettivi -come indicatori della memoria immediata- secondo i gradi delta Scala della memoria di Wechsler, per la riproduzione visiva e per Vorientamento. Inoltre i vantaggi notati nella reazione auditiv a media e nella frequenza critica dei lampeggiamenti dimostrano i suoi effetti sulla memoria rievocativa. I nostri risultati indicano che questo farmaco può essere utile nella terapia delle turbe della memoria da varia eziologia e che è neeessario un ulteriore approfondimento sul ruolo del ciclandelato in questo settore clinico.

Samenvatting

In een ongecontroleerd klinisch onderzoek, over een periode van 6 weken uitgevoerd bij 20 mannelijke patiënten tussen 49 en 68 jaar met geheugenstoornissen, bleek de dagelijkse toediening van 1200 tot 1600 mg cyclandelaat het geheugen effectief te verbeteren. Dat kon afgelezen worden uit psychiatrische, psychometrische en psychofysiologische metingen. Behandelingmet cyclandelaat leverde klinische effecten op die specifiek waren voor de punten visuele reproduktie en oriëntatie (indicatoren van het declaratieve geheugen) op de Weschler-geheugen-schaal. Bovendien toonden de verbeteringen van de gehoorreactie en de critical flicker fusion frequency aan dat de stof ook inwerkt op het procedurele geheugen. De resultaten wijzen er dus op dat dit middel therapeutisch werkzaam kan zijn bij geheugenstoornissen van allerlei aard en dat er meer onderzoek moet worden verricht naar de plaats van cyclandelaat in dit gebied.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albizzati MG, Bassi S, Calloni E, Sbacchi M, Frattola L. Cyclandelate versus flunarizine: double blind dummy study in a selected group of demented patients. Abstract no. 6, 3rd International Cyclospasmol Symposium, Helsinki, 14–15 November, 1986Google Scholar
  2. Ball JAC, Taylor AR. Effects of cyclandelate on mental function and cerebral blood flow in elderly patients. British Medical Journal 3: 525–528, 1967PubMedCrossRefGoogle Scholar
  3. Birkett DP. Vasodilators in geriatric psychiatry. Journal of the Medical Society. New Jersey 68: 619–623, 1971Google Scholar
  4. Davis G. A preliminary study on the effects of cyclandelate. Medical Journal of Australia 1: 305–317, 1971Google Scholar
  5. Eichorn O. The effect of cyclandelate on cerebral function. Vascular Disease 2: 305–317, 1965Google Scholar
  6. Fine EW, Lewis D, Villa-Landa I, Blakemore CB. The effects of cyclandelate on mental function in patients with arteriosclerotic brain disease. British Journal of Psychiatry 117: 157–161, 1970PubMedGoogle Scholar
  7. Gentilli C, Lugaresi E, Rebucci GG. On the action on cerebral circulation of a product formed by the esterification of mandelic acid with 3,5,5-trimethyl cyclohexanol. Clinical Therapeutics 22: 803–822, 1962Google Scholar
  8. Gillhespy RO. An evaluation of various peripheral vasodilators in the treatment of intermittent claudication. British Journal of Clinical Practice 13: 608–611, 1959PubMedGoogle Scholar
  9. Guy W. Clinical Global Impressions, in ECDEU Assessment Manual for Psychopharmacology, pp. 217–222, US Department of Health, Education, and Welfare, Rockville, Maryland, 1976Google Scholar
  10. Kuhn LA. Effect of cyclandelate upon cerebral blood flow in patients with “stroke”. Angiology 17: 422–430, 1966PubMedCrossRefGoogle Scholar
  11. Lehmann HE, Ban TA. Comparative clinical studies with psychotropic drugs: two year study with psychotropic drugs. EC- DEU Progress Report, Verdun, unpublished, 1963Google Scholar
  12. Leslie RE. Effects of cyclandelate in the treatment of circulatory disturbances. Texas State Medical Journal 56: 352–360, 1960Google Scholar
  13. O’Brien MD, Veall M. Effect of cyclandelate on cerebral cortex perfusion rates in cerebrovascular disease. Lancet 2: 729–730, 1966PubMedCrossRefGoogle Scholar
  14. Parsonage M. Cerebral vasodilators. British Medical Journal 3: 374, 1971CrossRefGoogle Scholar
  15. Reich T. Cyclandelate effect on circulatory measurements and exercise tolerance in chronic circulatory insufficiency of lower limbs. Journal of the American Geriatric Society 25: 202–205, 1977Google Scholar
  16. Ross JV. Objective evaluation of cyclandelate in the treatment of intermittent claudication associated with arteriosclerosis obliterans. Vascular Disease 2: 300–315, 1965Google Scholar
  17. Smith AL. Cyclandelate in the treatment of peripheral circulatory disease. Angiology 16: 1–7, 1965PubMedCrossRefGoogle Scholar
  18. Smith WL, Lowrey JB, Davis JA. The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency. Current Therapeutic Research 10: 613–618, 1968PubMedGoogle Scholar
  19. Squire LR. Mechanisms of memory. Science 232: 1612–1619, 1986PubMedCrossRefGoogle Scholar
  20. Van der Drift JHA. Ischemic cerebral lesions. Angiology 12: 401–418, 1961CrossRefGoogle Scholar
  21. Ward PJ. A clinical study of a spasmolytic agent [Cyclospasmol] in the treatment of elderly arteriosclerotic patients. Ulster Medical Journal 35: 129–136 (1965)Google Scholar
  22. Wechsler D. A standardized memory scale for clinical use. Journal of Psychology 19: 87–95, 1945CrossRefGoogle Scholar
  23. Young J, Hall P, Blackmore C. Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate. British Journal of Psychiatry 124: 177–180, 1974PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • Jambur Ananth
    • 1
  1. 1.University of CaliforniaLos AngelesUSA

Personalised recommendations